On Dec. 31, 2020, CytoDyn announced a research manuscript submitted by Nicholas J. Agresti, M.D. had been accepted for publication in the Journal of Translational Autoimmunity. The research findings were based on four critically ill COVID-19 patients treated with leronlimab under eIND.